In subgroup analyses by tumor type, HER3 over-expression in gastric cancers was associated with worse OS at both three years (OR = 1.69, 95% CI: 1.28–2.25) and five years (OR = 1.74, 95% CI: 1.26–2.41) (Table 1). This evidence concerns the gene ERBB3 and gastric cancer.